The manufacturing of gene editing (GE) components is a pivotal aspect of GE-based Cell and Gene Therapy development, requiring meticulous attention to product quality and regulatory compliance throughout the development lifecycle. In this webinar, we will discuss the key differences between GE components used from early discovery through to clinical application, and provide insight into how phase-appropriate components can be used to achieve clinical objectives while balancing quality and cost.
Dr. Jianpeng Wang
Senior Director of GMP Manufacturing, GenScript
Dr. Jianpeng Wang is the Senior Director of GMP Manufacturing at GenScript and a seasoned professional with a Ph.D. in chemistry and more than 15 years of experience in early R&D, process development, and GMP manufacturing of nucleic acids for gene editing. Under his leadership, Dr. Wang’s matrix team has delivered more than 100 batches of cGMP products to support over 40 projects globally. Specializing in the adoption and implementation of a phase-appropriate quality management system to ensure product quality and regulatory compliance, his thorough understanding of nucleic acid products and the dynamic regulatory landscape plays a pivotal role in ensuring GenScript meets and exceeds the needs of customers developing innovative therapies around the globe.
